SELLAS Q3 net loss narrows to $7.1M; Phase 3 AML interim analysis on track for Q4 2024

SELLAS Life Sciences Group, Inc.

2024-Q3 EPS reported -$0.42

Q3 net loss $7.1M ($0.10/sh) vs $9.3M ($0.33/sh) in Q3 2023; cash $21M.
Phase 3 REGAL (GPS) in AML: interim analysis of 60 events on track for Q4 2024.
FDA granted Rare Pediatric Disease Designation (RPDD) to GPS for pediatric AML.
SLS009 Phase 2a data in r/r AML to be presented at ASH Dec 8; 31% overall response.
R&D expenses $4.4M (-24% YoY); G&A expenses $3.0M (-14% YoY).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.